Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET

Company Participants

Rushmie Nofsinger - Vice President, Investor Relations & Corporate Affairs

Jay Backstrom - Chief Executive Officer

Mo Qatanani - Head of Research.

Ted Myles - Chief Operating Officer & Chief Financial Officer

Conference Call Participants

Michael Yee - Jefferies

Allison Bratzel - Piper Sandler

Tessa Romero - JPMorgan

Srikripa Devarakonda - Truist Securities

Etzer Darout - BMO Capital Markets

Andres Maldonado - H.C.Wainwright

Ernesto Rodriguez-Dumont - Cowen

Rushmie Nofsinger

Good morning. I'm Rushmie Nofsinger, Vice President of Corporate Affairs and Investor Relations at Scholar Rock. Welcome, and thank you for joining us today for our Q3 2023 Business Update Call. This call is audio-only. You can access the slides that we'll be referring to on the Events and Presentations section of the Investor Relations page on the Scholar Rock website.

Moving to Slide 2. Before we begin, I want to note that we'll be making various statements about Scholar Rock's expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date. Please refer to our SEC filings for the full disclosure of all the risks.

Turning to Slide 3. I'd like to introduce the members of the Scholar Rock team, who will be presenting during today's call and will be available for questions after the conclusion of the formal remarks. I am joined by Jay Backstrom, CEO of Scholar Rock; Ted Myles, Chief Operating Officer and Chief Financial Officer; and Mo Qatanani, Head of Research.

I will now turn it over to Jay.

Jay Backstrom

Thank you, Rushmie, and good morning, and welcome to our Q3 business update call. We've made excellent progress so far this year and in particular, in the third quarter, and I'm very excited about our future and believe we are well positioned for success.

Moving to Slide 4. Before I review the details of our progress, I want to start with Scholar Rock's pioneering approach to targeting TGFß super family of growth factors. The picture on the left of the slide depicts the latent complex that contains an active growth factor.

The scientific insight that led to the understanding of the structure of this latent complex is part of the foundation of our industry-leading platform that targets TGFß superfamily of growth factors by selectively and specifically blocking their activation by locking up the growth factor in the precursor or latent form. This highly specific approach limits the off-target effects that have been observed with less selective approaches that target the active forms of the growth factors or interfere with their receptors such as the activin receptors. Apitegromab, our lead clinical program targeting latent myostatin prevents the formation of the active form of myostatin, a negative regulator of muscle growth and leads to an increase in muscle mass and function in non-clinical models and is the first anti-myostatin therapy to demonstrate clinical proof-of-concept.